SAB Biotherapeutics, Inc. Company Profile

01:05 EDT 23rd March 2018 | BioPortfolio

SAB Biotherapeutics, Inc. (SAB), headquartered in Sioux Falls, S.D. is an established, biopharmaceutical company that is leading the science and manufacturing of immunoglobulin therapies. Utilizing some of the most advanced antibody science in the world, SAB is delivering the world’s first large scale platform to create fully human immunoglobulins. This natural production platform holds the promise of treatment of public health problems, rare conditions, long-term diseases and global pandemic threats.

News Articles [183 Associated News Articles listed on BioPortfolio]

#jobs #lifescience MS Applications Chemist – Biotherapeutics

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: MS Applications Chemist – Biotherapeutics .MA-Boston, MS Applications Chemi...

BRIEF—Hangzhou Just Biotherapeutics opens R&D center and GMP manufacturing facility

China-based Hangzhou Just Biotherapeutics (HJB), an organization dedicated to expanding global access…

ATUM, Just Biotherapeutics collaborate to speed up drug discovery

ATUM has signed a patent licensing agreement, which gives Just Biotherapeutics access to its Leap-In cell line development tools.

ATUM, Just Biotherapeutics collaborate to accelerate drug discovery

ATUM has entered into a patent licensing agreement with Just Biotherapeutics, providing access to the company’s Leap-In cell line development tools.

Protalix BioTherapeutics Treatment for Ulcerative Colitis Shows Positive Data

Protalix BioTherapeutics believes it’s on the right track in developing an oral medicine for ulcerative colitis that could potentially replace current TNF-inhibitor therapies that are administered v...

3 Best Biotherapeutics Stocks to Buy Right Now

Sometimes the biggest are also the best. That's the case for biotherapeutics stocks.

Stealth BioTherapeutics Granted Fast Track Designation for Elamipretide for the Treatment of Leber’s Hereditary Optic Neuropathy

BOSTON – December 18, 2017 – Stealth BioTherapeutics (Stealth), a clinical-stage biopharmaceutical company developing therapeutics to treat mitochondrial dysfunction, today announced that the U.S....

Aeglea BioTherapeutics Updates Phase I/II Trial Data

Aeglea BioTherapeutics announced new repeat dose data from its Phase I/II trial of AEB1102 (pegzilarginase) in patients with Arginase 1 Deficiency.

Drugs and Medications [14 Associated Drugs and Medications listed on BioPortfolio]


Plasma Protein Fraction (Human) 5%, USPPlasmanate®


Immune Globulin (Human)GamaSTAN™ S/DSolvent/Detergent Treated


Albumin (Human) 5%, USPPlasbumin ®-5


Albumin (Human) 5%, USPPlasbumin ®-5


Albumin (Human) 20%, USPPlasbumin®-20

PubMed Articles [22 Associated PubMed Articles listed on BioPortfolio]

Toward best practices in data processing and analysis for intact biotherapeutics by MS in quantitative bioanalysis.

Typically, quantitation of biotherapeutics from biological matrices by LC-MS is based on a surrogate peptide approach to determine molecule concentration. Recent efforts have focused on quantitation o...

Glycosimilarity assessment of biotherapeutics 1: Quantitative comparison of the N-glycosylation of the innovator and a biosimilar version of etanercept.

The carbohydrate moieties on the polypeptide chains in most glycoprotein based biotherapeutics and their biosimilars play essential roles in such major mechanisms of actions as antibody-dependent cell...

Targeting Receptor-Type Protein Tyrosine Phosphatases with Biotherapeutics: Is Outside-in Better than Inside-Out?

Protein tyrosine phosphatases (PTPs), of the receptor and non-receptor classes, are key signaling molecules that play critical roles in cellular regulation underlying diverse physiological events. Abe...

Population-specific design of de-immunized protein biotherapeutics.

Immunogenicity is a major problem during the development of biotherapeutics since it can lead to rapid clearance of the drug and adverse reactions. The challenge for biotherapeutic design is therefore...

Meeting report WHO informal consultation on development of guidelines on procedures and data requirements for changes to approved biotherapeutic products, Seoul, Republic of Korea, 27-28 April 2017.

In April 2017, WHO convened an informal consultation to develop WHO guidelines on procedures and data requirements for changes to approved biotherapeutic products. The objective of the meeting was to ...

Clinical Trials [4 Associated Clinical Trials listed on BioPortfolio]

Safety and Pharmacokinetics Study of Anthrax Immune Globulin Intravenous (AIGIV)

The purpose of this study is to: - evaluate the safety profile of a single intravenous administration of AIGIV (containing either 3.5 mg/kg, 7.0 mg/kg or 14.0 mg/kg anti-PA IgG) a...

A Study to Evaluate the Safety, Tolerability, and Efficacy of Subcutaneous Injections of Elamipretide (MTP-131) in Subjects With Genetically Confirmed Mitochondrial Disease Previously Treated in the Stealth BioTherapeutics SPIMM-201 Study

This is a Phase 2, randomized, double-blind, placebo-controlled crossover study which will enroll up to 36 subjects (anticipated) with genetically confirmed mitochondrial disease who have ...

The Effect of OASIS Ultra on Critical Sized Wound Healing

The aim of this study is to evaluate the speed and quality with which OASIS® Ultra (Healthpoint Biotherapeutics; Fort Worth, Texas) increases wound healing in the critical sized defect. ...

Personalized Immunotherapeutics for Antibiotic-resistant Infection

M. A. suffers from hypogammaglobulinemia that has been complicated by refractory Mycoplasma hominis septic arthritis. He has been receiving the antibiotic valnemulin under Emergency Invest...

Companies [95 Associated Companies listed on BioPortfolio]

Axial Biotherapeutics

Axial Biotherapeutics is a biopharmaceutical company harnessing the link between the human gut microbiome and the central nervous system to develop a new class of biotherapeutics ...

Napro Biotherapeutics Incorporated

NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent ...

Sephos Biotherapeutics

Sephos Biotherapeutics is a privately owned company focused on designing drugs for the treatment of cancer stem cells where the structure and biological activity of the drugs have...

Talecris Biotherapeutics Holdings Inc.

Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders i...

Talecris Biotherapeutics, Inc.

Talecris Biotherapeutics (Nasdaq: TLCR) is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-th...

More Information about "SAB Biotherapeutics, Inc." on BioPortfolio

We have published hundreds of SAB Biotherapeutics, Inc. news stories on BioPortfolio along with dozens of SAB Biotherapeutics, Inc. Clinical Trials and PubMed Articles about SAB Biotherapeutics, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of SAB Biotherapeutics, Inc. Companies in our database. You can also find out about relevant SAB Biotherapeutics, Inc. Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record